Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03016312
Title IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Acronym IMbassador250
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS


No variant requirements are available.